ABSTRACT
INTRODUCTION
Research on pathophysiological mechanisms of migraine have succeeded in elucidating many of the mechanisms of headache and identifying the involvement of trigeminovascular system. Migraine is a neurovascular disease in which a genetic disposition makes the brain of patients susceptible to a series of endogenous and exogenous trigger factors.
Migraine headache occurs as a result of neuronal-vascular chain of events in which genetic predisposition makes the brain of patients susceptible to a series of endogenous and exogenous trigger factors (1) . Headache pain in migraine attack depends on the activation of trigeminal afferents. Recent studies describe an association between migraine and specific immune molecules such as complements and interleukins. Thus, cytokines such as interleukin-2 (IL-2), IL-4, IL-6, IL-10, interferon gamma (IFN-γ), and granulocyte-macrophage colony-stimulating factor (GM-CSF) are proposed to have a relationship with migraine pathogenesis (2) . The known high rates of comorbidity between migraine and atopic diseases such as eczema and asthma is an important argument for a suspected immune system dysfunction in migraineurs (3) . However, the results of animal studies using nonsteroid anti-inflammatory drugs for inhibition of dural neurogenic plasma protein extravasation, also provide an evidence of the role of meningeal neurogenic inflammation in migraine (4, 5) . Cytokines are important mediators of the immune and inflammatory pathways and their receptors are widely expressed in the central nervous system; however, there are few studies evaluating cytokine levels in migraineurs (3) .
In this study, we aimed to investigate the contribution of cytokines in migraine pathogenesis by evaluating plasma TNF-α, IL-4, IL-5, IL-6, IL-10, and IFN-γ levels in migraineurs during and outside of attacks.
MATERIALS AND METHODS
A total of 70 migraine patients, between 17 and 55 years of age were recruited from the neurology outpatient clinics, headache specialty clinics, and emergency department of Firat University Medical Centre. The control group consisted of 19 healthy volunteers matched for sex and age. Patients were eligible for inclusion if they had at least a 6 month history of moderate or severe migraine attacks. Patients were healthy except for the headaches.
Patients were diagnosed with migraine without aura (MO) or migraine with aura (MA) according to ICHD-II (The International Headache Classification). Patients who had a history of drug use for migraine prophylaxis within the past 3 months, as well as those who had an acute or chronic systemic disease, allergic and autoimmune diseases, or history of chronic drug use, were excluded from the study. Approval was obtained from the local ethics committee and written informed consent was obtained from each patient before the study.
Study design
On arrival, their medical history, a physical and neurological examination, and electrocardiogram were recorded and routine blood laboratory tests were taken. Thereafter, venous blood specimen of 8 cc was collected from the forearm of the patients, centrifuged at 2000xg, and stored at -80 o C until the date of analysis. The measurements were carried out by ELISA (Enzymelinked immunosorbent assay) method. The values measured by a 2005 model Triturus micro ELISA device (Grifols Diagnostic, Spain) using Biosource kits were recorded in pg/mL.
Statistical Analysis
Statistical analyses were performed by SPSS 12.0 package program. The results were expressed as mean ± standard deviation (SD) values. Intergroup comparisons were carried out by Mann-Whitney U test. A p value <0.05 was recognized as statistically significant.
RESULTS
Patients were classified into 4 groups. First group included 15 patients with migraine with aura during attack (MAictal), second group included 15 patients with migraine with aura outside attack (MA-interictal), third group included 20 patients with migraine without aura during attack (MO-ictal), and fourth group included 20 patients showing migraine without aura outside attack (MOinterictal). Nineteen age-and gender-matched healthy individuals were enrolled as the control group. Female/ male ratio of the study groups was 49/21, it was 14/5 in the control group (p>0.05). The age of the patients varied between 17-55 years and mean age was calculated for each group. The mean age of the controls was 33 years (p>0.05). Age and gender distribution of the study and control groups are shown in the Table 1 .
Serum TNF-α levels were as follows; MA-ictal, 1.948±0.710; MA-interictal, 1.521±0.555; MO-ictal, 1.276±0.564, MOinterictal, 1.541±0.481 pg/mL. The control group had a serum TNF-α level of 0.895±0.520 pg/mL. There were statistically significant differences between the control group and MA-ictal (p<0.05), MA-interictal (p<0.05), and MO-interictal (p<0.05). Although MO-ictal exhibited higher TNF-α levels compared with the control group, but the difference was not statistically significant. When the study groups were compared with each other instead of the control group, a statistically significant difference was determined between MA-ictal and MO-ictal (p<0.05). Plasma concentration of IL-4 was 2.324±0.343 pg/mL in the control group, while it was 2.310±0.416, 2.294±0.310, 2.161±0.314, and 2.291±0.332 pg/mL in MA-ictal, MA- .05 between MA-interictal and control group, and p<0.05 between MO-ictal and control group. Although MO-interictal had a higher IL-6 concentration compared with the control group, the difference between was not statistically significant. Furthermore, MA-ictal, and MOictal (ictal groups) had higher IL-6 levels compared with MA-interictal, MO-interictal (interictal groups), however, these differences were not statistically significant, as well. Figure. Plasma concentration of IL-10 in the control group was 5.475±0.625 pg/mL, whereas it was 6.597±1.986, 5.788± 0.590, 6.543±0.871, and 5.871±0.756 pg/mL in MA-ictal, MA-interictal, MO-ictal, MO-interictal groups, respectively. Plasma IL-10 level was found to be statistically significantly higher in MA-ictal, and MO-ictal (ictal groups) than in control group (p<0.05), however, although plasma level of IL-10 was also higher in MA-interictal and MO-interictal (interictal groups) than in controls, the differences between were not statistically significant. Similarly, IL-10 levels were higher in MA-ictal, and MO-ictal (ictal groups) than in MA-interictal and MO-interictal (interictal groups), however, the differences were not statistically significant. Figure. 
DISCUSSION
While previous studies have shown that immune system contributes to the migraine pathophysiology, there have been conflicting study results and no consensus about the mechanism of this contribution. Different studies evaluating serum TNF-α levels in migraineurs have produced very different results. In 1990, Covelli et al. compared cases of migraine without aura with controls and determined an excessive release of TNF-α (6). Gallai et al. conducted a study on migraine patients with magnesium deficiency and found elevated serum IL-1, IL-6, and TNF-α levels (7). Sarchielli et al. determined temporary increases in TNF-α levels in internal jugular blood of 7 patients without aura during spontaneous attacks (8) . In our study, there was a statistically significant difference with regard to TNF-α levels between the control group and MA-ictal, control group and MA-interictal, control group and MO-interictal. MA-ictal displayed a significantly elevated TNF-α level compared with the MA-interictal, MOictal and MO-interictal. This finding was consistent with the studies (6, 8) reported in the literature and it was supportive of the opinion that hyperalgesic TNF-α release during a migraine attack contributes to the trigeminovascular hyperstimulation in migraine pathophysiology.
Previous studies evaluating plasma IL-4 levels in migraineurs have provided conflicting results. Martelletti et al. conducted a study on food-induced migraine cases and found that plasma GM-CSF and IFN-γ were increased, and IL-4 and IL-6 levels were decreased during attack (9) . In cases of isosorbid dinitrate-induced attacks, as in cases of spontaneous migraine, plasma IL-4 levels appear to be low (10) . In their first study, Munno et al. determined elevated IL-4 and IL-5 only in some migraine cases (11) , however, in their following study, they found immeasurably low plasma IL-4 and IL-5 levels in migraine patients without aura during attack. In the same study, following sumatriptan therapy, both cytokine concentrations displayed significant increases (2) . In a recent study of Sarchielli et al., IL-4 levels in jugular venous blood showed a decline during attack. Since Th2 cells are a major source of IL-4, authors explained the IL-4 decrease with Th2 inhibition during attack (8) . In our study, neither between migraine and control groups nor during attack and outside attack, there was no statistically significant difference in IL-4 levels. The studies we reviewed were based on a single migraine group, evaluating the during or outside migraine attacks. However, generally, slightly elevated IL-4 levels in our migraine groups can be explained with the increasing use of triptan, as well as with differences in methodology and measurements.
IL-6 acts as a mediator in peripheral acute phase response (12) . Furthermore, vasodilatation, a characteristic feature of headache phase, contributes to the drop in body temperature during attacks (3). IL-6 also induces hyperalgesia (13, 14) . Sarchielli et al. found raised IL-6 levels in internal jugular blood during the early hours of attack among cases of migraine without aura (8). Gergont et al. determined high IL-6 concentrations within the first hour of a migraine attack in children (15). Fidan et al. reported significantly higher serum IL-6 levels during attacks and interictals in migraine patients compared with the healthy controls (16) . Marteletti et al. determined reduced IL-6 levels during attack in food-induced migraine cases (9). Munno et al. reported that, similar to cytokines associated with allergic inflammation including IL-4 and IL-5; IL-10 expression by antigen-presenting cells can contribute to the alleviation of inflammation by its ability to inhibit the synthesis of non-specific proinflammatory cytokines similar to IL-1, IL-6, and TNF-α (2). In our study, serum IL-6 levels in MA-ictal, MA-interictal and MO-ictal were significantly higher than in controls. These results were consistent with some of the literature reporting significant differences between migraine patients and healthy individuals with regard to IL-6 levels. This increase in IL-6 level which has an important role as a proinflammatory cytokine, supports the opinion advocating involvement of neurogenic inflammation in migraine pathogenesis.
In our study, serum IL-10 levels were higher in interictal (outside attack) groups than in controls, the differences were not statistically significant. Similarly, IL-10 levels were higher in ictal groups than in interictal groups, however, the differences were not statistically significant. There are only a few reports about the role of IL-10 in migraine. IL-10 is also described as an inhibitor of cytokine synthesis. This result is consistent with the study of Munno and colleagues (2, 11) and the study of Fidan et al. who reported increases in serum IL-10 levels during attack (ictal period) (16) . Owing to the anti-inflammatory properties of IL-10, the increase in IL-10 levels during attacks has been proposed to be a reaction against some proinflammatory cytokines released throughout the active headache period (2) . On the contrary, same patients exhibited a decrease in plasma IL-10 levels and an increase in plasma IL-4 and IL-5 levels following sumatripan therapy which acts via 5HT1D receptors. Therefore, su-matripan therapy is noted to restore the cytokine profile observed during the interictal period (11) . The elevated IL-10 level during migraine attack can be understood as a response aiming to balance the increased level of plasma proinflammatory cytokines during attack.
IL-5 stimulates proliferation and differentiation of B cells and eosinophils (17) . The number of studies on IL-5 levels in migraine is limited. Munno et al. performed the first study in this subject and reported raised IL-5 levels in some cases (11) , however, in their following studies, they also noted immeasurably low IL-5 concentrations in cases of migraine without aura during attack (2). We did not observe a significant difference between plasma IL-5 levels of migraine patients with and without aura during attack and interictal.
The studies of serum IFN-γ levels in migraine are consistent with each other. Most of the studies report no changes in IFN-γ levels during attack and interictal periods of migraine patients (11, 16) . Only Marteletti et al. reported an elevated plasma IFN-γ level in food-induced migraine cases during attack (9) . In our study, consistent with most of the studies in the literature, no difference was determined between the study and control groups with regard to IFN-γ level.
The studies aimed to determine cytokine levels in migraine, have produced contentious results. Exact time of the day when the specimens are obtained during attack, appears to be an important factor affecting the meassurement values, because some hormones are well known to have diurnal rhythm. Particularly, the diurnal rhythm of cortisol should be borne in mind when evaluating the immune status of migraine patients. In this study, we were able to collect blood specimens upon presentation of migraine patients to the hospital during attack or interictal periods. It was not possible to perform a standardization relative to the onset of attacks or duration of the previous attack. Furthermore, failure to apply repeated measurements at different time points during attack or interictal, and non-exclusion of factors such as fasting and insomnia which could have an influence over cytokine release, appear to be the other limitations of our study. Another limitation of these measurements is to detect real change in the levels of cytokines, because of their short serum half-life and fast degradation and excretion.
In conclusion, the results acquired from this study supports the opinion advocating that immune system is involved in migraine. Furthermore, our results reveal that this immune involvement may be associated with characteristic clinical changes in migraine subgroups. Any differences noted would expand and clarify a neuroimmune hypothesis of migraine pathogenesis and lead to future diagnostic markers or therapeutic options or both for migraine. Determination of the prominent cytokine profiles in ictal and interictal periods may allow us to consider more satisfactory agents in terms of efficacy and side effects.
